Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The preferred primary treatment for iMCD is siltuximab, an anti-interleukin-6 antibody (anti–IL-6). Chemotherapy is reserved for severe cases or when anti-IL-6 is unavailable. The increased IL-6 signaling in iMC...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00035 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|